The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Drug Industry

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Drug Industry


High impact information on Drug Industry

  • There is every reason to believe that a multifaceted agent like raloxifene will find widespread use, and there will be continuing interest by the pharmaceutical industry in the development of new agents with even broader applications [6].
  • In addition to more basic studies on P-450 3A4, several areas of practical interest to the pharmaceutical industry require development [7].
  • Nicotine replacement therapy is heavily promoted to the general population by both the pharmaceutical industry and tobacco control advocates [8].
  • Similar pressures face the teaching of pharmacology in other countries and the situation, discussed here by Clive Page, Morley Sutter and Michael Walker, clearly has implications for academic pharmacology and the pharmaceutical industry [9].
  • The advent of cromolyn sodium therapy has been recognized as a significant advance by the pharmaceutical industry, which is rapidly developing a series of cromolyn-like drugs with similar properties [10].

Chemical compound and disease context of Drug Industry

  • Contrary to the claims frequently made by the pharmaceutical industry and regulatory agencies on both sides of the Atlantic, these results imply that it is likely that acceleration of regulatory review times in the US and the UK since the early 1990s is compromising drug safety [11].
  • The degradation of triphenylphosphine oxide (TPPO) in water, a toxic compound typically found in effluents from the pharmaceutical industry, by means of ultrasonic irradiation at 20 kHz has been investigated with emphasis on the effect of various parameters on conversion and acute toxicity [12].

Biological context of Drug Industry


Associations of Drug Industry with chemical compounds


Gene context of Drug Industry

  • The putative endothelin-converting enzyme (ECE) has been the focus of intense research, both within academia and the pharmaceutical industry [23].
  • Use of the Trp53+/- mouse presents the pharmaceutical industry with several challenges, one of which is managing the uncertainty created by a lack of precedents for regulatory decisions about some possible outcomes for short-term carcinogenicity assays [24].
  • To prevent this side effect, the pharmaceutical industry developed NSAIDs that selectively inhibit the cyclooxygenase 2 (COX-2) isoenzyme, which is inducible and expressed at sites of inflammation, while sparing the COX-1 isoenzyme, which is associated with gastric protection [25].
  • Emerging patent literature suggests significant interest in neuronal KCNQ modulation in the pharmaceutical industry and significant chemical diversity concerning KCNQ modulation [26].
  • The potential for drug development in several therapeutic areas has made galanin receptors a popular target for the pharmaceutical industry in recent years [27].

Analytical, diagnostic and therapeutic context of Drug Industry

  • PA of senkirkine in Kuan donghua was detected and the amount was found to be 79.1 microg/g. The results obtained indicate that the proposed MEKC method could potentially become an effective alternative tool for qualification control and quantitative analysis of herbal medicines in pharmaceutical industry [28].
  • A government-funded pediatric epilepsy group or consortium to conduct clinical trials similar to the successful Children's Oncology Group (COG) and regulations plus financial incentives that encourage the pharmaceutical industry to develop AEDs specifically for children are needed [29].
  • The great demand for improved long-acting injectable steroid contraceptives, particularly in developing countries, and the relative lack of interest from the pharmaceutical industry to develop such products stimulated WHO to launch a synthetic and screening programme to find improved, safe and acceptable injectable preparations [30].
  • However, because ABC transporters may limit the success of chemotherapy, there has been a considerable effort by the pharmaceutical industry to develop inhibitors of this transport process, and these are increasing in use [31].
  • Due to its major role in maintaining the water-retaining properties of the epidermis, ceramide is of great commercial potentials in cosmetic and pharmaceutical industries such as in hair and skin care products [32].


  1. The TESS database. Use in product safety assessment. Litovitz, T. Drug safety : an international journal of medical toxicology and drug experience. (1998) [Pubmed]
  2. Hormonal treatment of advanced breast cancer. Tellez, C., Jordan, V.C. Surg. Oncol. Clin. N. Am. (1995) [Pubmed]
  3. Study of the microbial aggregation in Mycobacterium using image analysis and electron microscopy. Borrego, S., Niubó, E., Ancheta, O., Espinosa, M.E. Tissue & cell. (2000) [Pubmed]
  4. Disease-modifying drugs for the early treatment of multiple sclerosis. Flachenecker, P. Expert review of neurotherapeutics. (2004) [Pubmed]
  5. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update. Weyer, C., Gautier, J.F., Danforth, E. Diabetes Metab. (1999) [Pubmed]
  6. Basic guide to the mechanisms of antiestrogen action. MacGregor, J.I., Jordan, V.C. Pharmacol. Rev. (1998) [Pubmed]
  7. Cytochrome P-450 3A4: regulation and role in drug metabolism. Guengerich, F.P. Annu. Rev. Pharmacol. Toxicol. (1999) [Pubmed]
  8. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. Pierce, J.P., Gilpin, E.A. JAMA (2002) [Pubmed]
  9. Wither, whether and whither pharmacology. Page, C.P., Sutter, M.C., Walker, M.J. Trends Pharmacol. Sci. (1994) [Pubmed]
  10. Therapy with cromolyn sodium. Bernstein, I.L., Johnson, C.L. Ann. Intern. Med. (1978) [Pubmed]
  11. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Abraham, J., Davis, C. Social science & medicine (1982) (2005) [Pubmed]
  12. Extent of sonochemical degradation and change of toxicity of a pharmaceutical precursor (triphenylphosphine oxide) in water as a function of treatment conditions. Emery, R.J., Papadaki, M., Freitas Dos Santos, L.M., Mantzavinos, D. Environment international. (2005) [Pubmed]
  13. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors. Haskell-Luevano, C., Holder, J.R., Monck, E.K., Bauzo, R.M. J. Med. Chem. (2001) [Pubmed]
  14. Flow injection analysis system for the supervision of industrial chromatographic downstream processing in biotechnology. Sosnitza, P., Irtel, F., Ulber, R., Busse, M., Faurie, R., Fischer, L., Scheper, T. Biosensors & bioelectronics. (1998) [Pubmed]
  15. Lactose: the milk sugar from a biotechnological perspective. Adam, A.C., Rubio-Texeira, M., Polaina, J. Critical reviews in food science and nutrition. (2004) [Pubmed]
  16. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Yuan, R., Madani, S., Wei, X.X., Reynolds, K., Huang, S.M. Drug Metab. Dispos. (2002) [Pubmed]
  17. Council of Emergency Medicine Residency Directors position on interactions between emergency medicine residencies and the pharmaceutical industry. Keim, S., Perina, D.G. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine. (2004) [Pubmed]
  18. Strategies for transgenic manipulation of monoterpene biosynthesis in plants. Mahmoud, S.S., Croteau, R.B. Trends Plant Sci. (2002) [Pubmed]
  19. The expanding pharmacopoeia for bipolar disorder. Mitchell, P.B., Malhi, G.S. Annu. Rev. Med. (2002) [Pubmed]
  20. Pegylation of interferon alfa: structural and pharmacokinetic properties. Pedder, S.C. Semin. Liver Dis. (2003) [Pubmed]
  21. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Ge, Y., Grossman, R.I., Udupa, J.K., Fulton, J., Constantinescu, C.S., Gonzales-Scarano, F., Babb, J.S., Mannon, L.J., Kolson, D.L., Cohen, J.A. Neurology (2000) [Pubmed]
  22. First-aid treatment of anaphylaxis to food: focus on epinephrine. Simons, F.E. J. Allergy Clin. Immunol. (2004) [Pubmed]
  23. Endothelin-converting enzymes. Opgenorth, T.J., Wu-Wong, J.R., Shiosaki, K. FASEB J. (1992) [Pubmed]
  24. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists. Floyd, E., Mann, P., Long, G., Ochoa, R. Toxicologic pathology. (2002) [Pubmed]
  25. Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications. Klasser, G.D., Epstein, J. Journal (Canadian Dental Association) (2005) [Pubmed]
  26. The therapeutic potential of neuronal KCNQ channel modulators. Gribkoff, V.K. Expert Opin. Ther. Targets (2003) [Pubmed]
  27. Galanin receptor subtypes. Wang, S., Gustafson, E.L. Drug News Perspect. (1998) [Pubmed]
  28. Separation and determination of toxic pyrrolizidine alkaloids in traditional Chinese herbal medicines by micellar electrokinetic chromatography with organic modifier. Yu, L., Xu, Y., Feng, H., Li, S.F. Electrophoresis (2005) [Pubmed]
  29. Antiepileptic drug development for "therapeutic orphans". Trevathan, E. Epilepsia (2003) [Pubmed]
  30. Long-acting contraceptive agents: design of the WHO Chemical Synthesis Programme. Crabbé, P., Archer, S., Benagiano, G., Diczfalusy, E., Djerassi, C., Fried, J., Higuchi, T. Steroids (1983) [Pubmed]
  31. Multiple drug resistance, antimutagenesis and anticarcinogenesis. Ferguson, L.R., Flora, S.D. Mutat. Res. (2005) [Pubmed]
  32. Enzymatic production of ceramide from sphingomyelin. Zhang, L., Hellgren, L.I., Xu, X. J. Biotechnol. (2006) [Pubmed]
WikiGenes - Universities